Current Technology Corporation Appoints Dr. Nigel John Rulewski To Medical And Scientific Advisory Board

VANCOUVER, British Columbia, Jan. 10 /PRNewswire-FirstCall/ -- The following was issued today by Robert Kramer, Director, Current Technology Corporation :

Current Technology is pleased to announce the appointment of Nigel John Rulewski, MB, BS, DRCOG, DCH to its Medical and Scientific Advisory Board. Dr. Rulewski will also serve as Special Medical Advisor to the Chief Executive Officer and Managing Director of Current Technology (UK) Ltd.

Dr. Rulewski has over 20 years experience in senior management positions in the pharmaceutical industry in both Europe and the United States. He served as Associate Medical Director of Fisons Corporation, Medical Director of Serono Inc., and Chief Medical Officer of Astra USA, Inc. (subsidiary of AstraZeneca Plc.), responsible for management of approximately 200 personnel and an R & D budget of $90 million per year. More recently, he established a pharmaceutical licensing and consulting company with a particular focus on the central nervous system (CNS) and oncology. Dr. Rulewski has identified, negotiated and in licensed 25 compounds from academia, biotechnology and established pharmaceutical companies in both Europe and the United States and was instrumental in the formation of two public oncology companies and prepared the intellectual property portfolios for three additional companies.

Dr. Rulewski brings a unique combination of abilities and experiences to the Company. He has been responsible for launching eight products in the US market, has directed dozens of submissions to the US Food and Drug Administration including NDAs, INDs, and ANDAs, has extensive experience in licensing and business development and most recently has been a significant contributor to fund raising activities in the tens of millions of dollars for a number of biotechnology companies.

A resident of Boston, Massachusetts and citizen of the United Kingdom, Dr. Rulewski received his medical training at St. Bartholomew’s Hospital Medical School (University of London) and was awarded the Ernest Withers Prize in Ophthalmology. He completed post-graduate education in two specialties and earned a Diploma of the Royal College of Obstetrics and Gynecologists and Diploma of Child Health of the Royal College of Physicians. After practicing medicine in the United Kingdom, Dr. Rulewski joined the pharmaceutical industry.

“The ETG technology being offered by Current Technology in the area of hair regrowth is a highly innovative approach to an area currently underserved by existing treatments,” said Dr. Rulewski. “This new approach offers what appears to be a side effect free method of restoration that will be of great interest to the aging baby boomers as well as to those experiencing hair loss as a side effect of chemotherapy.”

Anne Kramer, Current Technology Chairman, said, “We are especially appreciative of Dr. Rulewski’s interest in the use of our ETG technology to assist those experiencing chemotherapy induced hair loss. His considerable expertise in oncology research and regulatory affairs will be most beneficial as we look at moving our ETG technology forward in those areas.”

About Current Technology Corporation

Current Technology Corporation remains committed to developing its non-invasive pulsed electro-stimulation technology. This technology has enabled the company to develop two separate and distinct products emanating from the TrichoGenesis platform, thus far, that offer help for those concerned with their hair: ElectroTrichoGenesis (ETG) and CosmeticTrichoGenesis (CTG). Current Technology holds patents throughout the world and has spent over US $15 million in research and development of its TrichoGenesis platform and systems. The patents encompass the technology, methodology and design of the Company’s products.

Current Technology Corporation

CONTACT: Robert Kramer of Current Technology Corporation, 1-800-661-4247,or +1-604-684-2727, or rkramer@current-technology.com; or investors,Richard Hannon of Polestar Communications, +1-866-858-4100, for CurrentTechnology Corporation

MORE ON THIS TOPIC